LCTX
Lineage Cell Therapeutics In
AMEX · Biotechnology
$1.70
+0.02 (+1.19%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 10.92M | 8.41M | 226.72M | 231.61M | 228.84M |
| Net Income | -21,420,460 | -14,847,823 | -56,382,666 | -65,233,876 | -55,561,821 |
| EPS | — | — | — | — | — |
| Profit Margin | -195.9% | -186.1% | -24.9% | -28.2% | -24.3% |
| Rev Growth | +29.8% | +29.8% | +19.7% | -6.2% | +9.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 312.7K | 312.7K | 94.72M | 89.39M | 91.16M |
| Total Equity | 195.47M | 195.47M | 122.62M | 127.69M | 122.13M |
| D/E Ratio | 0.00 | 0.00 | 0.77 | 0.70 | 0.75 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -23,009,720 | -16,835,516 | -99,427,761 | -95,106,936 | -92,494,345 |
| Free Cash Flow | — | — | -46,193,350 | -33,113,271 | -35,128,048 |